Aridis Pharmaceuticals (ARDS)
(Delayed Data from OTC)
$0.00 USD
-0.01 (-99.00%)
Updated Sep 5, 2024 02:38 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Aridis Pharmaceuticals [ARDS]
Reports for Purchase
Showing records 1 - 20 ( 52 total )
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
3Q23: We Believe AR-301 Attractive For Near-Term Partnership Interest; Reiterate Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Recent Regulatory Developments Are Positive For AR-301; Reiterate Buy With a New $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
AR-301 Phase 3 Study Shows Positive Trends; Reiterate Buy With PT Adjusted to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Investment From the Cystic Fibrosis Foundation to Support AR-501 Development; Reiterate Buy Rating and $19 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
KOL Event Highlights the Need for a Therapy Like AR-301; Reiterate Buy and $19 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
AR-301 Phase 3 On-Track for Top-line Data in December; Reiterate Buy and $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
AR-301 and Immune-Based Approaches to Treating Infectious Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
AR-301 Phase 3 and AR-501 Phase 2a Top-Line Data on Track for 2H22; Reiterate Buy and $19 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Expecting Top-Line AR-301 Phase 3 Data and Multiple Readouts in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Expecting Top-Line AR-301 Phase 3 Data in 2H22; Reiterate Buy and $19 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Pan-Coronavirus Monoclonal Antibody Approach Protective Against Omicron and Delta; Reiterate Buy and $19 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Funding From the Bill and Melinda Gates Foundation; Reiterate Buy and $19 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
AR-701 Effective Against Omicron; Reiterate Buy Rating and $19 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Expecting AR-320 to be Complementary to AR-301; Reiterate Buy Rating and $19 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
In-Licensing of AR-320 Boosts the Pneumonia Franchise; Raising PT to $19 From $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
AR-501 and AR-712 Show Progress; Reiterate Buy and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Showing an Ability to Innovate and Compete With Limited Resources; Reiterate Buy Rating and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V